Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$14.76 +1.0%	$11.33	$6.38 ▼ $16.66	$1.43B	1.47	1.34 million shs	1.65 million shs
NVTS Navitas Semiconductor	$5.86 -3.0%	$6.88	$1.52 ▼ $9.48	$1.25B	3.02	21.51 million shs	12.77 million shs
SDGR Schrodinger	$19.51 -1.3%	$20.55	$16.60 ▼ $28.47	$1.44B	1.67	1.16 million shs	703,990 shs
VIGL Vigil Neuroscience	$8.05	$8.03	$1.31 ▼ $8.10	$383.91M	3.33	1.09 million shs	N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	-1.68%	-1.35%	+37.54%	+60.13%	-1.62%
NVTS Navitas Semiconductor	-0.49%	-2.74%	-19.68%	+18.66%	+106.14%
SDGR Schrodinger	-0.15%	+0.92%	-6.66%	-8.65%	-3.42%
VIGL Vigil Neuroscience	0.00%	0.00%	-0.12%	+2.16%	+129.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.8817 of 5 stars	3.6	3.0	2.9	1.7	0.6
NVTS Navitas Semiconductor	2.5086 of 5 stars	2.1	4.0	2.5	4.2	0.6
SDGR Schrodinger	3.0516 of 5 stars	3.3	3.0	2.5	3.3	0.6
VIGL Vigil Neuroscience	1.7917 of 5 stars	3.0	3.0	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.14	Buy	$19.67	33.24% Upside
NVTS Navitas Semiconductor	2.29	Hold	$5.65	-3.58% Downside
SDGR Schrodinger	2.67	Moderate Buy	$27.83	42.66% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	34.16% Upside

Current Analyst Ratings Breakdown

Latest VIGL, NVTS, SDGR, and AVDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	NVTS Navitas Semiconductor	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
8/26/2025	NVTS Navitas Semiconductor	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
8/21/2025	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $20.00
8/18/2025	NVTS Navitas Semiconductor	CJS Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/18/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $19.00
8/15/2025	SDGR Schrodinger	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$35.00 ➝ $20.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/8/2025	AVDL Avadel Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	AVDL Avadel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $24.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	8.47	N/A	N/A	$0.93 per share	15.87
NVTS Navitas Semiconductor	$83.30M	14.99	N/A	N/A	$1.82 per share	3.22
SDGR Schrodinger	$237.92M	6.04	N/A	N/A	$4.66 per share	4.19
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.03	N/A	246.00	N/A	-1.32%	-3.73%	-1.73%	11/11/2025 (Estimated)
NVTS Navitas Semiconductor	-$84.60M	-$0.65	N/A	N/A	N/A	-182.63%	-18.16%	-16.26%	11/3/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.48	N/A	N/A	N/A	-76.22%	-45.70%	-24.81%	11/11/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	11/6/2025 (Estimated)

Latest VIGL, NVTS, SDGR, and AVDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	$0.10	+$0.08	$0.10	$60.28 million	$68.13 million
8/6/2025	Q2 2025	SDGR Schrodinger	-$0.83	-$0.59	+$0.24	-$0.59	$52.03 million	$54.76 million
8/4/2025	Q2 2025	NVTS Navitas Semiconductor	-$0.05	-$0.05	N/A	-$0.25	$14.43 million	$14.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVTS Navitas Semiconductor	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.79	2.38
NVTS Navitas Semiconductor	N/A	8.23	7.59
SDGR Schrodinger	N/A	3.30	3.30
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
NVTS Navitas Semiconductor	46.14%
SDGR Schrodinger	79.05%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
NVTS Navitas Semiconductor	29.90%
SDGR Schrodinger	21.00%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	97.10 million	92.05 million	Optionable
NVTS Navitas Semiconductor	160	213.11 million	149.39 million	Optionable
SDGR Schrodinger	790	73.61 million	58.15 million	Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable

VIGL, NVTS, SDGR, and AVDL Headlines

Recent News About These Companies

Vigil Neuroscience Inc Merger and Leadership Changes

August 13, 2025 | theglobeandmail.com

Blair William & Co. IL Raises Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

August 10, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Average Recommendation of "Hold" from Brokerages

August 6, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Growth in Short Interest

August 3, 2025 | marketbeat.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

July 14, 2025 | businesswire.com

Vigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq

June 27, 2025 | nasdaq.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

June 25, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.comB

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.comM

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.comT

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)

May 28, 2025 | msn.com

Vigil Neuroscience Analyst Ratings and Price Targets | NASDAQ:VIGL | Benzinga

May 24, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VIGL, NVTS, SDGR, and AVDL Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$14.76 +0.14 (+0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$15.05 +0.29 (+1.99%)

As of 06:21 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Navitas Semiconductor NASDAQ:NVTS

$5.86 -0.18 (-2.98%)

Closing price 04:00 PM Eastern

Extended Trading

$5.91 +0.05 (+0.85%)

As of 06:25 PM Eastern

Navitas Semiconductor Corporation designs, develops, and markets gallium nitride power integrated circuits, silicon carbide, associated high-speed silicon system controllers, and digital isolators used in power conversion and charging. The company's products are used in mobile, consumer, data center, solar, electric vehicle, industrial motor drive, smart grid, and transportation applications. It operates in the United States, Europe, China, rest of Asia, and internationally. The company was founded in 2013 and is based in Torrance, California.

Schrodinger NASDAQ:SDGR

$19.51 -0.25 (-1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$19.50 -0.01 (-0.05%)

As of 06:01 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)

As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time